Back to top
more

GoodRx (GDRX)

(Delayed Data from NSDQ)

$4.50 USD

4.50
846,999

-0.03 (-0.66%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $4.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?

by Indrajit Bandyopadhyay

OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.

Zacks Equity Research

GDRX vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GDRX vs. HQY: Which Stock Is the Better Value Option?

Debanjana Dey headshot

DOCS Boosts Client Retention via Workflow Integration and AI Tools

by Debanjana Dey

Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx

by Zacks Equity Research

Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx are included in this Analyst Blog.

Nalak Das headshot

Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns

by Nalak Das

Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.

Zacks Equity Research

GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GDRX vs. PGNY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is GoodRx (GDRX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

GoodRx (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform

by Zacks Equity Research

GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

Zacks Equity Research

Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of 0% and 0.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks Equity Research

GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Zacks Equity Research

Organon (OGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 2.35% and 1.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Life Time Group Holdings (LTH) delivered earnings and revenue surprises of 23.81% and 1.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Zacks Equity Research

GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeMD (LFMD) delivered earnings and revenue surprises of -46.15% and 4.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Zacks Equity Research

Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?